Larazotide
Also known as: AT-1001 · Larazotide acetate
An 8-amino acid synthetic peptide designed to regulate tight junctions between intestinal epithelial cells. Directly targets intestinal permeability (leaky gut) and is the only compound in clinical trials specifically for tight junction regulation in celiac disease.
What is Larazotide? An 8-amino acid synthetic peptide designed to regulate tight junctions between intestinal epithelial cells. Directly targets intestinal permeability (leaky gut) and is the only compound in clinical trials specifically for tight junction regulation in celiac disease.
How does Larazotide work? Larazotide mimics the action of a naturally-occurring tight junction regulator, blocking zonulin signaling which normally opens intestinal tight junctions. By keeping tight junctions closed, it prevents luminal antigens and bacteria from crossing the gut barrier into systemic circulation — addressing the root mechanism of leaky gut.
Benefits of Larazotide: Reduces intestinal permeability (leaky gut); Specifically targets tight junction regulation; In Phase 2/3 clinical trials for celiac disease; Reduces gluten-induced symptoms in celiac patients; May help IBD, IBS, and food sensitivities; Gut barrier integrity restoration
Larazotide dosage: Clinical trials used 0.5mg-2mg three times daily before meals. Most research uses 500mcg-1mg TID.
Larazotide half-life: Short (~1 hour)
Research status: Clinical Trials
Source: PeptideWiki — https://www.peptide-wiki.net/peptides/larazotide
Mechanism of Action
Larazotide mimics the action of a naturally-occurring tight junction regulator, blocking zonulin signaling which normally opens intestinal tight junctions. By keeping tight junctions closed, it prevents luminal antigens and bacteria from crossing the gut barrier into systemic circulation — addressing the root mechanism of leaky gut.
Benefits
- Reduces intestinal permeability (leaky gut)
- Specifically targets tight junction regulation
- In Phase 2/3 clinical trials for celiac disease
- Reduces gluten-induced symptoms in celiac patients
- May help IBD, IBS, and food sensitivities
- Gut barrier integrity restoration
Side Effects & Risks
- Generally well tolerated in clinical trials
- Mild nausea (rare)
- Headache (reported in trials)
Where to Buy Larazotide
1 option across 1 vendor · Sorted cheapest first · All include direct product link
From
$65.00
All links are affiliate links — PeptideWiki earns a commission at no extra cost to you. Coupon codes apply at checkout. Prices and availability may change. Always verify COA before purchasing.
Storage & Reconstitution Guide
Storage Temperature
-20°C (lyophilized)
24 months (lyophilized), 28 days (reconstituted)
Reconstitution Solvent
Bacteriostatic water (BAC water)
Swirl gently — do not shake or vortex
Handling Notes
Protect lyophilized peptide from moisture and light. Once reconstituted, keep refrigerated. Discard if solution becomes cloudy or discolored. Use insulin syringe for precise dosing.
Step-by-Step Reconstitution
Gather supplies
BAC water, insulin syringe, alcohol swabs, vial
Disinfect tops
Swab rubber stoppers of both vials with alcohol
Draw BAC water
Pull desired mL of BAC water into syringe
Inject slowly
Inject BAC water down the side of the peptide vial, swirl gently to dissolve
Clinical Trials & Human Studies2 trials
Larazotide acetate reduces intestinal permeability in celiac disease
Larazotide 0.5mg three times daily significantly reduced intestinal permeability and celiac symptom scores in Phase 2 trial.
Phase 2b: Larazotide Acetate for Symptomatic Celiac Disease
RCT in 342 celiac disease patients on a gluten-free diet. Larazotide 0.5mg TID vs placebo: 26% decrease in symptomatic days (p=0.017); 31% increase in improved symptom days (p=0.034); GI symptom rating scale met primary endpoint (p=0.022).
Primary Outcome
GI symptom rating scale (GSRS) at 12 weeks
Tolerability
Well-tolerated; comparable to placebo AEs
Primary Endpoint
Met (p=0.022)
Improved Days Increase
31% more (p=0.034)
Symptomatic Days Reduction
26% fewer (p=0.017)
Molecular Structure
- CAS Number
- 1401028-24-7
- PubChem CID
- 44146842
- Molecular Weight
- 792.9 Da
- Mol. Formula
- C32H60N12O12S2
- Amino Acids
- 8-AA peptide
- Wikipedia
- View article
Research Protocol
- Dose Range
- 250–2000 mcg
- Frequency
- 3x daily, 30 min before meals
- Cycle
- 6-12 weeks
- Half-Life
- Short (~1 hour)
- Routes
- oral
- Notes
- Clinical trials used 0.5mg-2mg three times daily before meals. Most research uses 500mcg-1mg TID.
Legal & Regulatory Status
Sold for research purposes only. Not for human use. Laws vary by country.
Commonly Stacked With
View all peptide stacks →External Resources
PeptideWiki Research Team
Evidence-based research data sourced from PubMed and ClinicalTrials.gov · Last updated: February 25, 2026
Frequently Asked Questions About Larazotide
What is Larazotide?▾
An 8-amino acid synthetic peptide designed to regulate tight junctions between intestinal epithelial cells. Directly targets intestinal permeability (leaky gut) and is the only compound in clinical trials specifically for tight junction regulation in celiac disease.
What are the benefits of Larazotide?▾
Reduces intestinal permeability (leaky gut)
What are the benefits of Larazotide?▾
Specifically targets tight junction regulation
What are the side effects of Larazotide?▾
Generally well tolerated in clinical trials
What is the recommended dosage for Larazotide?▾
Clinical trials used 0.5mg-2mg three times daily before meals. Most research uses 500mcg-1mg TID.
How long should a Larazotide cycle last?▾
6-12 weeks
More Healing & Recovery Peptides
View all Healing & Recovery peptides →Cardiogen
Heart peptide bioregulator
A tetrapeptide cardiac bioregulator from the Khavinson series targeting myocardial tissue. Normalizes myocardial cell function, reduces cardiac oxidative stress, and provides cardioprotection against ischemia and aging-related cardiac decline. Studied for heart failure, cardiomyopathy, and post-infarction recovery.
Cartalax
Cartilage peptide bioregulator
A cartilage and bone-targeting peptide bioregulator from the Khavinson series. Studied for arthritis, osteochondrosis, fracture recovery, and joint aging. Stimulates chondrocyte proliferation and collagen synthesis in cartilage tissue, supporting structural repair and maintenance of joint integrity.
ARA-290
Cibinetide
A synthetic 11-amino acid peptide that mimics the tissue-protective actions of erythropoietin without its erythropoietic effects. Highly effective for neuropathic pain and nerve repair.
Svetinorm
BioLiver
A liver-targeting tetrapeptide bioregulator. Normalizes hepatocyte function, reduces liver fibrosis, improves bile acid metabolism, and protects against hepatotoxicity. Studied for NAFLD, alcohol-related liver damage, hepatitis recovery, and liver aging.